Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. (CYRX) is the issuer in Schedule 13G/A Amendment No. 4, in which Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch each reported that they may have been deemed to beneficially own 2,418,947 common shares as of September 30, 2026, approximately 4.8% of shares outstanding. The shares were directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP. Under investment management agreements, Cadian Capital Management, LP exercises exclusive voting and investment power; each reporting person reported shared voting and dispositive power over the shares and zero sole voting or dispositive power.
Cryoport, Inc. (CYRX) Chief Scientific Officer Mark W. Sawicki sold 10,000 shares of common stock on November 10, 2026, at a weighted average price of $19.9261 per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.27. Sawicki directly held 92,356 shares after the sale. No Rule 10b5-1 plan is reported.
Daniel M. Hancock, a director of Cryoport, Inc. (CYRX), exercised options for 74,379 common shares on November 9, 2026, at exercise prices of $9.73, $12.65 and $7.00 per share. He also sold 74,379 shares at a weighted average of $20.207 per share. The transactions occurred automatically pursuant to a trading plan adopted May 27, 2026.
Cryoport, Inc. officer Mark Sawicki reported a proposed sale of 10,000 common shares, with an aggregate market value of $199,261 and an approximate sale date of November 10, 2026.
Cryoport, Inc. director Daniel M. Hancock reported a proposed sale of 74,379 common shares, with an aggregate market value of $1,420,638.90 and an approximate sale date of November 9, 2026. The shares were acquired from the issuer through exercise of stock options for cash. The notice gives May 27, 2026, as the Rule 10b5-1 plan adoption date.
Cryoport, Inc. (CYRX) reported third-quarter 2026 revenue of $50.220 million, compared with $44.233 million a year earlier; nine-month revenue was $146.989 million versus $130.727 million. Third-quarter revenue included $28.564 million from Life Sciences Services and $21.656 million from Life Sciences Products.
Loss from continuing operations was $10.852 million for the quarter, compared with $6.696 million in Q3 2025; the nine-month loss was $28.539 million versus $25.448 million. Net cash provided by operating activities was $10.080 million for the first nine months, compared with $9.499 million used in the same 2025 period.
Cash, cash equivalents and short-term investments totaled $393.076 million at September 30, 2026. The $186.2 million principal amount of 0.75% Convertible Senior Notes is due and payable in December 2026. Cryoport completed the $133.0 million sale of its CRYOPDP business in June 2025; its results are presented as discontinued operations, including a $1.112 million loss for the first nine months of 2026.
Cryoport, Inc. reported third-quarter 2026 revenue of $50.220 million, up 14% from $44.233 million a year earlier. Life Sciences Services revenue increased 18% to $28.564 million, including 25% growth in BioStorage/BioServices; Life Sciences Products revenue rose 8% to $21.656 million. For the first nine months, revenue was $146.989 million, compared with $130.727 million. Life Sciences Services revenue was $83.431 million and Life Sciences Products revenue was $63.558 million during that period.
GAAP loss from continuing operations was $10.852 million, versus $6.696 million a year earlier, while adjusted EBITDA from continuing operations was $1.103 million, compared with a $649,000 loss. For the first nine months, adjusted EBITDA from continuing operations was $867,000, compared with a $4.382 million loss a year earlier. Cryoport raised full-year 2026 revenue guidance to $197 million to $199 million. As of September 30, 2026, Cryoport supported 23 commercial therapies and 788 clinical trials, including 99 Phase 3 trials. Cash and cash equivalents were $279.179 million and short-term investments were $113.897 million as of that date.
Cryoport, Inc. is reported to have a significant shareholder group led by Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (together, the reporting persons). As of June 30, 2026, they may have been deemed to beneficially own 2,920,681 shares of Cryoport common stock.
This position represented approximately 5.8% of the outstanding common stock, based on 50,648,491 shares outstanding as of June 30, 2026. The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, over which Cadian Capital Management, LP exercises exclusive voting and investment power pursuant to investment management agreements. Voting and dispositive power over all reported shares is described as shared, with no sole voting or dispositive power.
Morgan Stanley and an affiliate report reduced ownership in Cryoport, Inc. common stock. Morgan Stanley reports shared voting power over 2,190,498 shares and shared dispositive power over 2,246,650 shares, representing 4.5% of the class. Morgan Stanley Capital Services LLC reports shared voting and dispositive power over 2,163,384 shares, representing 4.3% of the class. Both entities state that, as of the reporting date, each has ceased to be the beneficial owner of more than five percent of Cryoport’s common stock. The filing clarifies that it reflects securities beneficially owned, or deemed beneficially owned, by specified Morgan Stanley operating units, excluding any disaggregated units under applicable SEC guidance.
Cryoport, Inc. director and President/CEO Jerrell Shelton reported selling 28,800 shares of common stock on August 11, 2026 at a weighted average price of $14.9092 per share. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on May 11, 2026 and terminated on August 11, 2026. Following this transaction, Shelton directly held 1,201,814 shares of Cryoport common stock.